Personalised medicine
151 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Emma Pettengale
Scoop.it!

The 6th Annual Personalized and Precision Medicine Conference 2014 Agenda

The 6th Annual Personalized and Precision Medicine Conference 2014 Agenda | Personalised medicine | Scoop.it
This is The 6th Annual Personalized and Precision Medicine Conference Agenda. The conference will be exploring the ways in which Personalized & Precision Medicine is reshaping healthcare. This conference brings together multiple stakeholders, including payers, molecular diagnostics companies, genome analysis/interpretation companies, clinicians and many others in order to provide attendees with a holistic view of the personalized medicine landscape.
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

About Us - Icahn School of Medicine at Mount Sinai

About Us - Icahn School of Medicine at Mount Sinai | Personalised medicine | Scoop.it
personalized therapeutics for cardiometabolic diseases
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

Precision Medicine and Targeted Therapy

Precision Medicine and Targeted Therapy | Personalised medicine | Scoop.it
Information about the role that targeted therapies play in precision medicine.
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

PharmaTelevision - Is it possible to transform cells back from being cancerous to non cancerous?

PharmaTelevision - Is it possible to transform cells back from being cancerous to non cancerous? | Personalised medicine | Scoop.it
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

Experimental Northwest Biotherapeutics Drug Gets First Slot Under UK Early Access Scheme

Experimental Northwest Biotherapeutics Drug Gets First Slot Under UK Early Access Scheme | Personalised medicine | Scoop.it
NW Bio's Cancer Vaccine Is The First Drug To Be Designated By UK Authorities As A "Promising Innovative Medicine" BETHESDA, Md., Sept. 16, 2014
Emma Pettengale's insight:

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,

more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

Oncology Central

Oncology Central | Personalised medicine | Scoop.it
RT @OncologyCentral: Investigators identify predictive #biomarkers of ovarian #cancer response in the blood http://t.co/36DE5tmBMn #Ovarian…
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

Novel epitope for binding of HIV antibodies has major drug delivery implications - FierceDrugDelivery

Novel epitope for binding of HIV antibodies has major drug delivery implications - FierceDrugDelivery | Personalised medicine | Scoop.it
Novel epitope for binding of HIV antibodies has major drug delivery implications
FierceDrugDelivery
The discovery of a new HIV antibody by researchers at the U.S.
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: A systematic review

The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: A systematic review | Personalised medicine | Scoop.it
Rheumatology Medical Article: The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: A systematic review (RT @MDLinx: The estimated frequency of antiphospholipid antibodies in young adults with...
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

Novel Immunotherapy Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients | MD Anderson Cancer Center

Novel Immunotherapy Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients | MD Anderson Cancer Center | Personalised medicine | Scoop.it
A new vaccine candidate, (GP2), provides evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful drug.
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

Arthritis Research & Therapy | Full text | Moving towards personalized medicine in rheumatoid arthritis

To develop personalized medicine strategies for improvement of patient management in rheumatoid arthritis, the clinical and molecular properties of the individual patients need to be well characterized.
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

PROSTVAC Mechanism Of Action - YouTube

Visualization of the mechanism of action for PROSTVAC, an active immunotherapy product candidate for the treatment of asymptomatic or minimally symptomatic m...
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

Why targeted drug doesn't benefit patients with early-stage lung cancer

Why targeted drug doesn't benefit patients with early-stage lung cancer | Personalised medicine | Scoop.it
y targeted drug doesn't benefit patients with early-stage lung cancer
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

Personalized medicine in CLL: current status and... [Cancer Lett. 2014] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

Personalized treatment for stress-related diabetes

Personalized treatment for stress-related diabetes | Personalised medicine | Scoop.it
A treatment for type 2 diabetes that targets the disease mechanism itself -- and not just the symptoms -- has been developed by researchers. For the first time, knowledge about the individual patient’s genetic risk profile is being used. The treatment completely restores the capacity to secrete insulin, which is impaired by the risk gene.
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers

NEW YORK, Dec. 8 /PRNewswire/ -- The market for personalized medicine in the United States is already $232...
more...
Keith McGuinness's curator insight, October 7, 2014 1:53 PM

To adapt another line from the report to accommodate the power of apps to illuminate the behavioral profile, in contrast to genomics…

 

Imagine that the data flowing from behavior change apps enabled physicians to identify an individual's (or group of behaviorally similar individuals) susceptibility to chronic disease, predict how a given patient will respond to a behavioral therapy, eliminate unnecessary treatments including unnecessary drugs, increase the effectiveness of behavioral treatments and, ultimately, improve health outcomes.


We can do this, but to do so we must 'disrupt' the FREE for service business model of health and wellness apps.  

Scooped by Emma Pettengale
Scoop.it!

New biomedical implants heal bones faster, focus on personalized medicine

New biomedical implants heal bones faster, focus on personalized medicine | Personalised medicine | Scoop.it
The two studies funded by the National Science Fund (NSF) in the US and the High Impact Research (HIR) program in Malaysia tackled the issue of bone-implant integration from different angles. In the first study appearing on the front cover of the July issue of Applied Surface Science, researchers demonstrated a mechanically superior bioactive coating based on magnesium silicates rather than the commercially available calcium phosphate which develops microcracks during preparation and delaminates under pressure. The new material owing to its lower thermal mismatch with titanium can prolong the durability of load-bearing orthopedic implants and reduce chances of post-surgery complications.
The other study published in the American Chemical Society's Applied Materials & Interfaces reported a method for fabricating titanium implants with special surface topographies which double the chance of cell viability in early stages. The new technique is also much simpler as compared to the existing ones and therefore enables the preparation of personalized implants at the fraction of time and cost while offering a higher mechanical reliability.
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

OSE Pharma Release Texopi0174 A New Ray Of Hope For Lung Cancer Immu

A promising treatment in advanced stage lung cancer After convincing Phase 2 results observed in a United States trial, OSE Pharma’s team have
Emma Pettengale's insight:

Texopi®, a personalised treatment, is designed to benefit patients who carry the tissue marker HLA A2 (45% of the population) who are affected by invasive or metastatic cancers. Globally, each year, 1.58 million1 new cases are discovered. In France every year 29, 9492 people discover that they are affected by lung cancer, of which more than 60% are at an advanced stage, either by a local expansion (invasive), or a metastatic stage. These tumours cannot be operated on. The effect of current chemotherapy and radiotherapy is unfortunately still limited.

more...
No comment yet.
Rescooped by Emma Pettengale from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Dupilumab Highly Effective in Moderate-to-Severe Atopic Dermatitis

Dupilumab Highly Effective in Moderate-to-Severe Atopic Dermatitis | Personalised medicine | Scoop.it

METHODS

We performed randomized, double-blind, placebo-controlled trials involving adults who had moderate-to-severe atopic dermatitis despite treatment with topical glucocorticoids and calcineurin inhibitors. Dupilumab was evaluated as monotherapy in two 4-week trials and in one 12-week trial and in combination with topical glucocorticoids in another 4-week study. End points included the Eczema Area and Severity Index (EASI) score, the investigator's global assessment score, pruritus, safety assessments, serum biomarker levels, and disease transcriptome.

 RESULTS

In the 4-week monotherapy studies, dupilumab resulted in rapid and dose-dependent improvements in clinical indexes, biomarker levels, and the transcriptome. The results of the 12-week study of dupilumab monotherapy reproduced and extended the 4-week findings: 85% of patients in the dupilumab group, as compared with 35% of those in the placebo group, had a 50% reduction in the EASI score (EASI-50, with higher scores in the EASI indicating greater severity of eczema) (P<0.001); 40% of patients in the dupilumab group, as compared with 7% in the placebo group, had a score of 0 to 1 (indicating clearing or near-clearing of skin lesions) on the investigator's global assessment (P<0.001); and pruritus scores decreased (indicating a reduction in itch) by 55.7% in the dupilumab group versus 15.1% in the placebo group (P<0.001). In the combination study, 100% of the patients in the dupilumab group, as compared with 50% of those who received topical glucocorticoids with placebo injection, met the criterion for EASI-50 (P=0.002), despite the fact that patients who received dupilumab plus glucocorticoids used less than half the amount of topical glucocorticoids used by those who received placebo plus the topical medication (P=0.16). Adverse events, such as skin infection, occurred more frequently with placebo; nasopharyngitis and headache were the most frequent adverse events with dupilumab.

 CONCLUSIONS

Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity. Side-effect profiles were not dose-limiting. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers,NCT01259323, NCT01385657, NCT01639040, and NCT01548404.)

  

Supported by Regeneron Pharmaceuticals and Sanofi.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

 

 


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, September 10, 2014 6:44 PM

These results if confirmed in Phase III trials make Dupilumab the IL4 and IL13 targeting monoclonal antibody, the first effective treatment for Atopic Dermatitis.

 

The results showed dramatic efficacy of the sanofi/Regeneron mab. This may get the drug breakthrough therapy designation and fast track priority review and approval by the FDA and EMA.

 

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

Lisa A. Beck, M.D., Diamant Thaçi, M.D., Jennifer D. Hamilton, Ph.D., Neil M. Graham, M.D., Thomas Bieber, M.D., Ph.D., M.D.R.A., Ross Rocklin, M.D., Jeffrey E. Ming, M.D., Ph.D., Haobo Ren, Ph.D., Richard Kao, Dr.P.H., Eric Simpson, M.D., Marius Ardeleanu, M.D., Steven P. Weinstein, M.D., Ph.D., Gianluca Pirozzi, M.D., Ph.D., Emma Guttman-Yassky, M.D., Ph.D., Mayte Suárez-Fariñas, Ph.D., Melissa D. Hager, M.A., Neil Stahl, Ph.D., George D. Yancopoulos, M.D., Ph.D., and Allen R. Radin, M.D.

N Engl J Med 2014; 371:130-139July 10, 2014DOI: 10.1056/NEJMoa1314768

Scooped by Emma Pettengale
Scoop.it!

NIH scientists discover new HIV antibody - Vaccine News Daily

NIH scientists discover new HIV antibody Vaccine News Daily The NIH team said that because 35O22 only binds to viral spikes that closely resemble those that naturally occur in HIV, any vaccines that elicit 35O22-like antibodies will need to mimic...
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

Our Personalised Medicine Programme | Cancer Research UK - YouTube

Using genetic screening to guide treatment, Cancer Research UK's Stratified Medicine Programme will help bring the right drugs to the right patients. For mor...
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

Business Viewpoint: Personalized medicine in a changing health care environment

Business Viewpoint: Personalized medicine in a changing health care environment | Personalised medicine | Scoop.it
Visit the post for more. (Business Viewpoint: Personalized medicine in a changing health care environment http://t.co/JWdxwVREP0)
more...
No comment yet.
Scooped by Emma Pettengale
Scoop.it!

MOLOGEN: Initiation of phase III IMPALA study with immunotherapy MGN1703 in colorectal
cancer

MOLOGEN: Initiation of phase III IMPALA study with immunotherapy MGN1703 in colorectal<br/>cancer | Personalised medicine | Scoop.it
FirstWord Pharma - Gain Access to the Information You Need Track the Companies, Products, and Regulatory Areas of Most Interest to You (RT @Xemadeyaka14: MOLOGEN: Initiation of phase III IMPALA study with immunotherapy MGN1703 in colorectal cancer...
more...
No comment yet.